Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma: Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression

Cancer

Volumn 92, Issue 12, 2001, Pages 2965-2974

  Tsuda, Hitoshi ^a   Akiyama, Futoshi ^b   Terasaki, Hiroshi ^c   Hasegawa, Tadashi ^d   Kurosumi, Masafumi ^e   Shimadzu, Mitsunobu ^a   Yamamori, Shunji ^a   Sakamoto, Goi ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c CANCER INSTITUTE   (Japan)

^d Mitsubishi Kagaku Bio Clinical Laboratories Inc   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

Author keywords

Breast carcinoma; DNA amplification; Fluorescent in situ hybridization (FISH); HER 2 neu (c erb B 2); Immunohistochemistry (IHC); Interobserver agreement

Indexed keywords

NEU DIFFERENTIATION FACTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OBSERVER VARIATION; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM INVASIVENESS; OBSERVER VARIATION; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 0035892771     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO;2-A     Document Type: Article

References (24)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Follow-up study of HER-2/neu amplification in primary breast cancer
3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
4. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
5. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
6. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
7. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2
8. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
9. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
10. Increased HER2 with U.S. Food and Drug Administration-approved antibody
11. Immunohistochemical assays for HER2 overexpression
12. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer
13. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
14. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases
15. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma
16. HER2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement
17. Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma
18. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
19. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer. A preliminary report
20. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials
21. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
22. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: Its correlation with gene amplification and long-term survival of patients
23. Coefficient of agreement for nominal scale
24. The measurement of observer agreement for categorical data